Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging

Neurobiology of Aging
Grazyna LietzauCesare Patrone

Abstract

The nigrostriatal dopaminergic system (NDS) controls motor activity, and its impairment during type 2 diabetes (T2D) progression could increase Parkinson's disease risk in diabetics. If so, whether glycemia regulation prevents this impairment needs to be addressed. We investigated whether T2D impairs the NDS and whether dipeptidyl peptidase-4 inhibition (DPP-4i; a clinical strategy against T2D but also neuroprotective in animal models) prevents this effect, in middle-aged mice. Neither T2D (induced by 12 months of high-fat diet) nor aging (14 months) changed striatal dopamine content assessed by high-performance liquid chromatography. However, T2D reduced basal and amphetamine-stimulated striatal extracellular dopamine, assessed by microdialysis. Both the DPP-4i linagliptin and the sulfonylurea glimepiride (an antidiabetic comparator unrelated to DPP-4i) counteracted these effects. The functional T2D-induced effects did not correlate with NDS neuronal/glial alterations. However, aging itself affected striatal neurons/glia, and the glia effects were counteracted mainly by DPP-4i. These findings show NDS functional pathophysiology in T2D and suggest the preventive use of two unrelated anti-T2D drugs. Moreover, DPP-4i counteracted...Continue Reading

References

Oct 1, 1988·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·H J GundersenB Pakkenberg
Jan 11, 1996·The New England Journal of Medicine·D A BennettD A Evans
Dec 21, 2005·Parkinsonism & Related Disorders·Karen M PowersHarvey Checkoway
Jan 26, 2007·Diabetes Care·Gang HuJaakko Tuomilehto
Sep 1, 2007·Neurology·Kelly Claire SimonAlberto Ascherio
Jan 23, 2009·Nature Neuroscience·Siming ShenPatrizia Casaccia-Bonnefil
Jan 24, 2009·Proceedings of the National Academy of Sciences of the United States of America·Yazhou LiNigel H Greig
Mar 30, 2010·Journal of the Neurological Sciences·Yoshihiro MiyakeUNKNOWN Fukuoka Kinki Parkinson's Disease Study Group
Sep 10, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Fuzheng GuoDavid Pleasure
Mar 8, 2011·Diabetes Care·Qun XuHonglei Chen
Jun 28, 2011·Experimental Neurology·J K MorrisJ A Stanford
Nov 24, 2011·Diabetes Care·Emanuele CeredaGianni Pezzoli
Jan 21, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·María Hidalgo-FigueroaJosé López-Barneo
Jun 8, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·Rodolfo SavicaWalter A Rocca
Jun 12, 2012·Cell·Hongxia RenDomenico Accili
Apr 18, 2013·The Journal of Endocrinology·Hiranya PintanaSiriporn C Chattipakorn
Aug 8, 2013·Expert Opinion on Pharmacotherapy·Carolyn F Deacon, Jens J Holst
Sep 10, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Anton ReinerRichard L M Faull
Mar 14, 2014·The Lancet. Diabetes & Endocrinology·Cesare PatroneDan Lindholm
Apr 11, 2014·Neurobiology of Disease·Jose A Santiago, Judith A Potashkin
Apr 29, 2014·Biochimica Et Biophysica Acta·Andreia Barateiro, Adelaide Fernandes
Dec 3, 2014·Neuropharmacology·Noha N NassarDalaal M Abdallah
Feb 12, 2015·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Vladimer DarsaliaCesare Patrone
Dec 29, 2015·Frontiers in Bioscience (Scholar Edition)·Bjoern Neumann, Ilias Kazanis
May 4, 2016·Basal Ganglia·David SulzerMargaret E Rice
Jul 20, 2016·Movement Disorders : Official Journal of the Movement Disorder Society·Per SvenningssonJonas F Ludvigsson
Aug 20, 2016·Science·Richard M Ransohoff
May 19, 2017·Movement Disorders : Official Journal of the Movement Disorder Society·Timothy J CollierJeffrey H Kordower
Jul 28, 2017·American Journal of Alzheimer's Disease and Other Dementias·Nehru Sai Suresh ChalichemBasavan Duraiswamy
Aug 5, 2017·Journal of Parkinson's Disease·Dilan AthaudaThomas Foltynie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aging & Diabetes

This feed focuses on the role of the aging process on developing diabetes.

Aging-Associated Metabolic Disorders

Age is associated with many metabolic disorders including cardiovascular diseases, type 2 diabetes, stroke and heart disease. The mediators in aging process have been suggested to play a part in the cellular processes responsible for these metabolic disorders. Here is the latest research on aging-associated metabolic disorders.